The FDA issued a warning about the potential for inadvertent, increased radiation exposure in patients receiving cardiac PET scans with Rb-82 chloride injection from CardioGen-82.
Health care professionals should stop using CardioGen-82 for cardiac positron emission tomography (PET) scans, the FDA said. The manufacturer, Bracco Diagnostics Inc. is voluntarily recalling CardioGen-82, according to an FDA statement released Tuesday afternoon.
CardioGen-82 consists of a generator used at clinical sites to produce rubidium-82 chloride injection. A CardioGen-82 PET scan is one of a variety of nuclear medicine scans that use radioactive drugs to evaluate the heart.
On July 15, the FDA issued a warning about the potential for inadvertent, increased radiation exposure in patients receiving cardiac PET scans with Rb-82 chloride injection from CardioGen-82. The warning came after the agency received reports of two patients who received more radiation than expected from CardioGen-82 due to a “strontium breakthrough” problem. The patients’ exposure came to light when they traveled to the United States and set off airport radiation alarms despite having had PET scans two and four months earlier. Rb-82 has a half-life of 75 seconds; strontium’s is 25 days.
The FDA says it believes that the risk of harm is minimal, with the estimated amount of excess radiation the two patients received being similar to that of cumulative exposure to certain other types of heart scans.
Still, the FDA determined that the current CardioGen-82 manufacturing procedures fail to ensure reliable performance of the generator used to produce the Rb-82 chloride injection. The FDA is also investigating the testing procedures used to detect strontium breakthrough at the clinical sites that use CardioGen-82.
The agency recommends that health care professionals use alternatives to the CardioGen-82 generator when planning nuclear medicine cardiac scans. The FDA says it’s working with the Nuclear Regulatory Commission and Bracco to determine the root cause for the increased radiation in the two patients. The agency is also investigating whether additional patients received inadvertent radiation exposure.
Improving Adherence to Best Practices for Incidental Abdominal Aortic Aneurysms on CT and MRI
November 5th 2024In recent interviews, Eric Rohren, M.D., and Krishna Nallamshetty, M.D., discuss the potential of abdominal aortic aneurysms (AAAs) to progress into life-threatening consequences and an emerging AI-powered tool that may bolster adherence to best practice recommendations in radiology reporting of incidental AAA findings on CT and MRI.
Artifact Reduction Drives Technology Advances with Updated Version of Echelon Synergy MRI System
October 30th 2024Emerging technologies included with the 10th version of the 1.5T MRI platform include Synergy DLR Clear and Synergy Vision that are geared toward mitigating common challenges with artifacts.